Eric Lavonas
Concepts (305)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Snake Bites | 28 | 2023 | 59 | 10.860 |
Why?
| Antivenins | 24 | 2019 | 59 | 7.560 |
Why?
| Cardiopulmonary Resuscitation | 28 | 2023 | 232 | 7.530 |
Why?
| Agkistrodon | 14 | 2019 | 19 | 6.920 |
Why?
| Heart Arrest | 15 | 2023 | 305 | 4.910 |
Why?
| Immunoglobulin Fab Fragments | 11 | 2019 | 74 | 4.110 |
Why?
| Crotalid Venoms | 8 | 2019 | 30 | 3.170 |
Why?
| Viperidae | 5 | 2013 | 12 | 1.810 |
Why?
| Emergency Medical Services | 17 | 2023 | 635 | 1.750 |
Why?
| Out-of-Hospital Cardiac Arrest | 10 | 2023 | 79 | 1.740 |
Why?
| Immunoglobulin Fragments | 5 | 2013 | 16 | 1.670 |
Why?
| Cardiology Service, Hospital | 5 | 2020 | 30 | 1.530 |
Why?
| Cardiology | 6 | 2020 | 338 | 1.290 |
Why?
| Upper Extremity | 2 | 2018 | 85 | 1.190 |
Why?
| Emergency Service, Hospital | 13 | 2020 | 1922 | 1.080 |
Why?
| Lower Extremity | 2 | 2018 | 345 | 0.970 |
Why?
| Drug Overdose | 6 | 2020 | 273 | 0.910 |
Why?
| American Heart Association | 10 | 2023 | 313 | 0.890 |
Why?
| Poison Control Centers | 5 | 2016 | 102 | 0.880 |
Why?
| Analgesics, Non-Narcotic | 4 | 2017 | 122 | 0.870 |
Why?
| Poisoning | 4 | 2016 | 113 | 0.850 |
Why?
| Acetaminophen | 5 | 2017 | 261 | 0.830 |
Why?
| Analgesics, Opioid | 5 | 2021 | 785 | 0.820 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2018 | 302 | 0.800 |
Why?
| Agranulocytosis | 2 | 2012 | 32 | 0.800 |
Why?
| Humans | 86 | 2023 | 122796 | 0.800 |
Why?
| Levamisole | 2 | 2012 | 19 | 0.790 |
Why?
| Recovery of Function | 4 | 2019 | 610 | 0.770 |
Why?
| Buprenorphine | 2 | 2014 | 129 | 0.750 |
Why?
| Consensus | 14 | 2023 | 554 | 0.720 |
Why?
| Nonprescription Drugs | 2 | 2011 | 69 | 0.710 |
Why?
| Hematologic Tests | 1 | 2019 | 24 | 0.700 |
Why?
| Crotalus | 1 | 2019 | 18 | 0.690 |
Why?
| Advanced Cardiac Life Support | 9 | 2022 | 24 | 0.690 |
Why?
| Cocaine | 2 | 2012 | 157 | 0.670 |
Why?
| Noninvasive Ventilation | 1 | 2019 | 31 | 0.660 |
Why?
| Patient Outcome Assessment | 2 | 2017 | 130 | 0.620 |
Why?
| Drug Hypersensitivity | 1 | 2018 | 82 | 0.620 |
Why?
| Intubation, Intratracheal | 2 | 2019 | 243 | 0.620 |
Why?
| Carbon Monoxide Poisoning | 3 | 2014 | 8 | 0.610 |
Why?
| Physical Examination | 1 | 2019 | 253 | 0.610 |
Why?
| Treatment Outcome | 21 | 2023 | 9692 | 0.590 |
Why?
| Animals | 24 | 2020 | 34133 | 0.590 |
Why?
| Lithium Compounds | 1 | 2015 | 11 | 0.550 |
Why?
| United States | 21 | 2023 | 13272 | 0.540 |
Why?
| Adult | 29 | 2023 | 32385 | 0.530 |
Why?
| Drug Contamination | 2 | 2012 | 60 | 0.500 |
Why?
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2014 | 37 | 0.490 |
Why?
| Skin Diseases, Bacterial | 1 | 2014 | 24 | 0.490 |
Why?
| Renal Dialysis | 2 | 2015 | 395 | 0.490 |
Why?
| Prescription Drug Diversion | 1 | 2014 | 10 | 0.490 |
Why?
| Soft Tissue Infections | 1 | 2014 | 29 | 0.480 |
Why?
| Narcotics | 1 | 2014 | 53 | 0.470 |
Why?
| Poisons | 1 | 2014 | 29 | 0.470 |
Why?
| Uncertainty | 1 | 2014 | 107 | 0.470 |
Why?
| Hyperbaric Oxygenation | 2 | 2011 | 42 | 0.470 |
Why?
| Indazoles | 1 | 2014 | 61 | 0.470 |
Why?
| Child | 23 | 2023 | 19561 | 0.460 |
Why?
| Serum Sickness | 1 | 2012 | 6 | 0.430 |
Why?
| Antinematodal Agents | 1 | 2012 | 5 | 0.430 |
Why?
| Cannabinoids | 1 | 2014 | 120 | 0.420 |
Why?
| Hypersensitivity, Immediate | 1 | 2012 | 59 | 0.410 |
Why?
| Young Adult | 12 | 2019 | 11094 | 0.410 |
Why?
| Drug Design | 1 | 2012 | 163 | 0.400 |
Why?
| Acid-Base Equilibrium | 1 | 2011 | 32 | 0.400 |
Why?
| False Negative Reactions | 1 | 2011 | 59 | 0.400 |
Why?
| Opioid-Related Disorders | 2 | 2019 | 412 | 0.400 |
Why?
| Anti-Infective Agents | 1 | 2014 | 248 | 0.400 |
Why?
| Middle Aged | 18 | 2019 | 28563 | 0.390 |
Why?
| Severity of Illness Index | 6 | 2019 | 2784 | 0.390 |
Why?
| Emergencies | 6 | 2020 | 159 | 0.390 |
Why?
| Clinical Laboratory Techniques | 1 | 2011 | 93 | 0.370 |
Why?
| Liver Failure | 1 | 2010 | 94 | 0.370 |
Why?
| Female | 27 | 2023 | 63629 | 0.370 |
Why?
| Male | 24 | 2019 | 59639 | 0.370 |
Why?
| Double-Blind Method | 3 | 2019 | 1711 | 0.360 |
Why?
| Premature Birth | 2 | 2023 | 304 | 0.360 |
Why?
| Antitussive Agents | 1 | 2009 | 7 | 0.340 |
Why?
| Common Cold | 1 | 2009 | 12 | 0.340 |
Why?
| Aged, 80 and over | 8 | 2019 | 6845 | 0.330 |
Why?
| Hemorrhage | 1 | 2013 | 663 | 0.330 |
Why?
| Acetylcysteine | 2 | 2010 | 150 | 0.330 |
Why?
| Aspirin | 1 | 2011 | 344 | 0.330 |
Why?
| Naloxone | 2 | 2020 | 88 | 0.310 |
Why?
| Decision Support Techniques | 1 | 2011 | 392 | 0.300 |
Why?
| Evidence-Based Medicine | 6 | 2020 | 731 | 0.300 |
Why?
| First Aid | 5 | 2023 | 15 | 0.290 |
Why?
| Clinical Trials as Topic | 3 | 2023 | 985 | 0.280 |
Why?
| Infant | 12 | 2021 | 8523 | 0.280 |
Why?
| Time Factors | 4 | 2019 | 6682 | 0.280 |
Why?
| Child, Preschool | 11 | 2020 | 9755 | 0.270 |
Why?
| Follow-Up Studies | 5 | 2019 | 4768 | 0.270 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2019 | 1260 | 0.270 |
Why?
| Adolescent | 11 | 2020 | 18948 | 0.260 |
Why?
| Practice Guidelines as Topic | 4 | 2021 | 1519 | 0.250 |
Why?
| Administration, Sublingual | 2 | 2014 | 14 | 0.240 |
Why?
| Tablets | 2 | 2014 | 39 | 0.240 |
Why?
| Digoxin | 1 | 2023 | 29 | 0.240 |
Why?
| Infant, Newborn | 9 | 2023 | 5430 | 0.240 |
Why?
| Aged | 10 | 2019 | 20495 | 0.230 |
Why?
| Pediatrics | 2 | 2022 | 1009 | 0.230 |
Why?
| Algorithms | 1 | 2011 | 1593 | 0.230 |
Why?
| Benzodiazepines | 1 | 2023 | 125 | 0.220 |
Why?
| Risk Factors | 8 | 2021 | 9381 | 0.220 |
Why?
| Emergency Treatment | 2 | 2023 | 117 | 0.220 |
Why?
| Liver | 1 | 2010 | 1827 | 0.210 |
Why?
| Disability Evaluation | 3 | 2023 | 291 | 0.210 |
Why?
| International Classification of Functioning, Disability and Health | 1 | 2021 | 4 | 0.210 |
Why?
| Adrenergic beta-Antagonists | 1 | 2023 | 334 | 0.200 |
Why?
| Asphyxia | 1 | 2020 | 23 | 0.190 |
Why?
| Fentanyl | 1 | 2020 | 70 | 0.180 |
Why?
| Global Health | 1 | 2023 | 352 | 0.180 |
Why?
| Minimal Clinically Important Difference | 1 | 2019 | 6 | 0.180 |
Why?
| Blood Coagulation Disorders | 1 | 2002 | 213 | 0.170 |
Why?
| Dose-Response Relationship, Drug | 3 | 2017 | 1981 | 0.170 |
Why?
| Incidence | 2 | 2018 | 2527 | 0.170 |
Why?
| Hypothermia, Induced | 1 | 2019 | 69 | 0.170 |
Why?
| Observational Studies as Topic | 1 | 2019 | 91 | 0.170 |
Why?
| Vasoconstrictor Agents | 2 | 2019 | 128 | 0.160 |
Why?
| Multicenter Studies as Topic | 1 | 2019 | 247 | 0.160 |
Why?
| Airway Management | 1 | 2019 | 74 | 0.160 |
Why?
| Comparative Effectiveness Research | 1 | 2019 | 142 | 0.160 |
Why?
| Early Medical Intervention | 1 | 2018 | 56 | 0.160 |
Why?
| Resuscitation | 1 | 2020 | 279 | 0.160 |
Why?
| Extracorporeal Circulation | 2 | 2019 | 15 | 0.160 |
Why?
| Delivery of Health Care, Integrated | 1 | 2020 | 247 | 0.150 |
Why?
| Pregnancy Complications, Cardiovascular | 2 | 2015 | 72 | 0.150 |
Why?
| Prospective Studies | 3 | 2021 | 6704 | 0.150 |
Why?
| ROC Curve | 1 | 2019 | 494 | 0.150 |
Why?
| Interviews as Topic | 1 | 2019 | 601 | 0.150 |
Why?
| Activities of Daily Living | 2 | 2021 | 361 | 0.150 |
Why?
| Needs Assessment | 1 | 2019 | 345 | 0.150 |
Why?
| Calcium | 1 | 2023 | 1244 | 0.140 |
Why?
| Calcium Channel Blockers | 1 | 2017 | 121 | 0.140 |
Why?
| Fluoride Poisoning | 1 | 2016 | 4 | 0.140 |
Why?
| Heart | 1 | 2020 | 649 | 0.140 |
Why?
| Reproducibility of Results | 3 | 2019 | 2977 | 0.140 |
Why?
| Salicylates | 1 | 2016 | 32 | 0.140 |
Why?
| Quality of Life | 2 | 2019 | 2457 | 0.140 |
Why?
| Bupropion | 1 | 2016 | 40 | 0.140 |
Why?
| Near Drowning | 1 | 2015 | 4 | 0.140 |
Why?
| Patient Care Team | 1 | 2020 | 520 | 0.140 |
Why?
| Cysteine | 1 | 2017 | 187 | 0.140 |
Why?
| Information Systems | 1 | 2016 | 67 | 0.140 |
Why?
| Lithium Carbonate | 1 | 2015 | 6 | 0.140 |
Why?
| Cardiac Tamponade | 1 | 2015 | 16 | 0.140 |
Why?
| Fat Emulsions, Intravenous | 1 | 2015 | 31 | 0.140 |
Why?
| Immunologic Factors | 2 | 2019 | 228 | 0.140 |
Why?
| Lead Poisoning, Nervous System, Adult | 1 | 2015 | 2 | 0.130 |
Why?
| Blood Proteins | 1 | 2017 | 249 | 0.130 |
Why?
| Water-Electrolyte Imbalance | 1 | 2015 | 34 | 0.130 |
Why?
| Chemical and Drug Induced Liver Injury | 1 | 2017 | 141 | 0.130 |
Why?
| Hypothermia | 1 | 2015 | 34 | 0.130 |
Why?
| Anaphylaxis | 2 | 2015 | 144 | 0.130 |
Why?
| Age Factors | 2 | 2020 | 3114 | 0.130 |
Why?
| Observer Variation | 1 | 2016 | 314 | 0.130 |
Why?
| Psychometrics | 1 | 2019 | 672 | 0.130 |
Why?
| Proportional Hazards Models | 1 | 2018 | 1184 | 0.130 |
Why?
| Ergotism | 1 | 2014 | 1 | 0.130 |
Why?
| Ergotamine | 1 | 2014 | 2 | 0.130 |
Why?
| Drama | 1 | 2014 | 2 | 0.130 |
Why?
| Medicine in Literature | 1 | 2014 | 4 | 0.130 |
Why?
| Literature, Modern | 1 | 2014 | 3 | 0.130 |
Why?
| Wit and Humor as Topic | 1 | 2014 | 5 | 0.130 |
Why?
| Muscle Weakness | 1 | 2015 | 83 | 0.120 |
Why?
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2014 | 17 | 0.120 |
Why?
| Hypokalemia | 1 | 2014 | 31 | 0.120 |
Why?
| Pain | 2 | 2019 | 746 | 0.120 |
Why?
| Toxicology | 1 | 2014 | 30 | 0.120 |
Why?
| Foreign Bodies | 1 | 2015 | 100 | 0.120 |
Why?
| Opioid Peptides | 1 | 2013 | 4 | 0.120 |
Why?
| Pharmacovigilance | 1 | 2013 | 12 | 0.120 |
Why?
| Sex Factors | 1 | 2019 | 1860 | 0.120 |
Why?
| Time-to-Treatment | 1 | 2015 | 157 | 0.120 |
Why?
| Pulmonary Embolism | 1 | 2015 | 190 | 0.120 |
Why?
| Crime | 1 | 2013 | 57 | 0.120 |
Why?
| Drug Combinations | 1 | 2014 | 292 | 0.110 |
Why?
| Opiate Substitution Treatment | 1 | 2014 | 95 | 0.110 |
Why?
| Housing | 1 | 2014 | 125 | 0.110 |
Why?
| Statistics as Topic | 1 | 2014 | 314 | 0.110 |
Why?
| Drug Packaging | 1 | 2013 | 45 | 0.110 |
Why?
| Hypotension | 1 | 2014 | 135 | 0.110 |
Why?
| Costs and Cost Analysis | 1 | 2013 | 211 | 0.110 |
Why?
| Half-Life | 1 | 2012 | 147 | 0.110 |
Why?
| Wounds, Gunshot | 1 | 2015 | 178 | 0.110 |
Why?
| Retrospective Studies | 5 | 2015 | 13433 | 0.100 |
Why?
| Central Nervous System | 1 | 2013 | 244 | 0.100 |
Why?
| Surveys and Questionnaires | 3 | 2023 | 4882 | 0.100 |
Why?
| Universities | 1 | 2014 | 356 | 0.100 |
Why?
| Evidence-Based Emergency Medicine | 1 | 2011 | 4 | 0.100 |
Why?
| Self Report | 1 | 2015 | 730 | 0.100 |
Why?
| Disease Outbreaks | 1 | 2014 | 333 | 0.100 |
Why?
| Regression Analysis | 1 | 2013 | 1018 | 0.100 |
Why?
| Crack Cocaine | 1 | 2010 | 9 | 0.100 |
Why?
| Databases, Factual | 1 | 2016 | 1287 | 0.100 |
Why?
| Disease Models, Animal | 1 | 2020 | 3799 | 0.100 |
Why?
| Leukopenia | 1 | 2010 | 27 | 0.090 |
Why?
| Phenotype | 1 | 2019 | 3070 | 0.090 |
Why?
| Liver Function Tests | 1 | 2010 | 114 | 0.090 |
Why?
| Enzyme Inhibitors | 1 | 2014 | 836 | 0.090 |
Why?
| Delphi Technique | 1 | 2011 | 170 | 0.090 |
Why?
| Pilot Projects | 1 | 2015 | 1477 | 0.090 |
Why?
| Cross-Sectional Studies | 3 | 2017 | 4734 | 0.090 |
Why?
| Program Evaluation | 1 | 2014 | 880 | 0.090 |
Why?
| Oxygen Inhalation Therapy | 1 | 2011 | 142 | 0.090 |
Why?
| Leukocyte Count | 1 | 2010 | 309 | 0.090 |
Why?
| Neutropenia | 1 | 2010 | 134 | 0.090 |
Why?
| Percutaneous Coronary Intervention | 1 | 2015 | 535 | 0.090 |
Why?
| Patient Selection | 1 | 2013 | 717 | 0.090 |
Why?
| Injections, Intravenous | 2 | 2010 | 217 | 0.090 |
Why?
| Bone Marrow | 1 | 2010 | 257 | 0.080 |
Why?
| Risk | 1 | 2011 | 890 | 0.080 |
Why?
| Cardiovascular Diseases | 1 | 2020 | 1859 | 0.080 |
Why?
| Brain | 1 | 2020 | 2540 | 0.080 |
Why?
| Pharmacy Service, Hospital | 1 | 2009 | 88 | 0.080 |
Why?
| Respiration Disorders | 1 | 2009 | 67 | 0.080 |
Why?
| Administration, Oral | 1 | 2010 | 786 | 0.080 |
Why?
| Nervous System Diseases | 1 | 2011 | 265 | 0.080 |
Why?
| Pregnancy | 3 | 2015 | 5854 | 0.080 |
Why?
| Congresses as Topic | 1 | 2009 | 208 | 0.080 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 240 | 0.080 |
Why?
| Anti-Arrhythmia Agents | 2 | 2018 | 132 | 0.080 |
Why?
| Disease Progression | 1 | 2015 | 2546 | 0.080 |
Why?
| Wounds and Injuries | 1 | 2015 | 813 | 0.080 |
Why?
| Pregnancy Complications | 1 | 2012 | 462 | 0.080 |
Why?
| Hypersensitivity | 1 | 2010 | 259 | 0.070 |
Why?
| Antidotes | 1 | 2009 | 160 | 0.070 |
Why?
| Respiration, Artificial | 3 | 2019 | 596 | 0.070 |
Why?
| Dosage Forms | 1 | 2005 | 11 | 0.070 |
Why?
| Registries | 1 | 2013 | 2020 | 0.060 |
Why?
| Colorado | 1 | 2014 | 4325 | 0.060 |
Why?
| Disease Management | 1 | 2008 | 591 | 0.060 |
Why?
| Cooperative Behavior | 2 | 2020 | 410 | 0.060 |
Why?
| Biomedical Research | 1 | 2009 | 630 | 0.060 |
Why?
| Treatment Failure | 1 | 2004 | 348 | 0.060 |
Why?
| Anesthesiologists | 1 | 2022 | 15 | 0.050 |
Why?
| Fingers | 1 | 2002 | 83 | 0.050 |
Why?
| Air Ambulances | 1 | 2002 | 47 | 0.050 |
Why?
| Necrosis | 1 | 2002 | 238 | 0.050 |
Why?
| Recurrence | 1 | 2004 | 998 | 0.050 |
Why?
| Ventilators, Mechanical | 2 | 2010 | 52 | 0.050 |
Why?
| Quality Assurance, Health Care | 2 | 2015 | 362 | 0.050 |
Why?
| Bradycardia | 2 | 2010 | 58 | 0.050 |
Why?
| North Carolina | 2 | 2014 | 116 | 0.040 |
Why?
| Interdisciplinary Communication | 1 | 2020 | 195 | 0.040 |
Why?
| Hyperthermia, Induced | 1 | 2019 | 67 | 0.040 |
Why?
| Amiodarone | 1 | 2018 | 24 | 0.040 |
Why?
| Consensus Development Conferences as Topic | 1 | 2018 | 31 | 0.040 |
Why?
| Lidocaine | 1 | 2018 | 40 | 0.040 |
Why?
| Epinephrine | 1 | 2019 | 166 | 0.040 |
Why?
| Magnesium | 1 | 2018 | 156 | 0.040 |
Why?
| Monitoring, Physiologic | 2 | 2010 | 288 | 0.040 |
Why?
| Advisory Committees | 1 | 2018 | 229 | 0.040 |
Why?
| Critical Care | 1 | 2022 | 563 | 0.040 |
Why?
| Systems Analysis | 1 | 2015 | 23 | 0.030 |
Why?
| Health Personnel | 1 | 2021 | 603 | 0.030 |
Why?
| Atrial Fibrillation | 2 | 2010 | 392 | 0.030 |
Why?
| Reference Values | 1 | 2017 | 789 | 0.030 |
Why?
| Chelating Agents | 1 | 2015 | 75 | 0.030 |
Why?
| Thailand | 1 | 2014 | 10 | 0.030 |
Why?
| Orphan Drug Production | 1 | 2014 | 6 | 0.030 |
Why?
| Blood Pressure | 1 | 2002 | 1713 | 0.030 |
Why?
| Thoracic Surgical Procedures | 1 | 2015 | 65 | 0.030 |
Why?
| Biological Availability | 1 | 2014 | 129 | 0.030 |
Why?
| Placebo Effect | 1 | 2014 | 53 | 0.030 |
Why?
| Product Surveillance, Postmarketing | 1 | 2014 | 70 | 0.030 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2014 | 60 | 0.030 |
Why?
| Walking | 1 | 2017 | 435 | 0.030 |
Why?
| Peripheral Vascular Diseases | 1 | 2014 | 102 | 0.030 |
Why?
| Fatal Outcome | 1 | 2014 | 299 | 0.030 |
Why?
| United States Food and Drug Administration | 1 | 2014 | 186 | 0.030 |
Why?
| Drug Interactions | 1 | 2014 | 356 | 0.030 |
Why?
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2012 | 14 | 0.030 |
Why?
| Hemoperfusion | 1 | 2012 | 4 | 0.030 |
Why?
| Sorption Detoxification | 1 | 2012 | 3 | 0.030 |
Why?
| Uterine Hemorrhage | 1 | 2012 | 36 | 0.030 |
Why?
| Tissue and Organ Procurement | 1 | 2015 | 243 | 0.030 |
Why?
| Pregnancy, Ectopic | 1 | 2012 | 54 | 0.030 |
Why?
| Renal Replacement Therapy | 1 | 2012 | 74 | 0.030 |
Why?
| Pelvis | 1 | 2012 | 94 | 0.030 |
Why?
| International Cooperation | 1 | 2012 | 182 | 0.030 |
Why?
| Abdominal Pain | 1 | 2012 | 141 | 0.020 |
Why?
| Data Collection | 1 | 2014 | 667 | 0.020 |
Why?
| Health Policy | 1 | 2014 | 356 | 0.020 |
Why?
| Drug Administration Routes | 1 | 2010 | 44 | 0.020 |
Why?
| Nausea | 1 | 2010 | 110 | 0.020 |
Why?
| Vomiting | 1 | 2010 | 126 | 0.020 |
Why?
| Public Health | 1 | 2014 | 480 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2010 | 396 | 0.020 |
Why?
| Drug Storage | 1 | 2009 | 61 | 0.020 |
Why?
| Safety | 1 | 2010 | 307 | 0.020 |
Why?
| Drug Utilization | 1 | 2009 | 183 | 0.020 |
Why?
| Research Design | 1 | 2014 | 1002 | 0.020 |
Why?
| Ultrasonography | 1 | 2012 | 740 | 0.020 |
Why?
| Quality Improvement | 1 | 2015 | 1004 | 0.020 |
Why?
| Hospitalization | 1 | 2017 | 1914 | 0.020 |
Why?
| Biomarkers | 1 | 2017 | 3662 | 0.020 |
Why?
| Societies, Medical | 1 | 2009 | 741 | 0.020 |
Why?
| South Carolina | 1 | 2003 | 37 | 0.010 |
Why?
| Debridement | 1 | 2003 | 78 | 0.010 |
Why?
| Blood Transfusion | 1 | 2003 | 312 | 0.010 |
Why?
| Hemodynamics | 1 | 2003 | 1036 | 0.010 |
Why?
| Asthma | 1 | 2010 | 2130 | 0.010 |
Why?
| Obesity | 1 | 2010 | 2786 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 2003 | 1562 | 0.010 |
Why?
|
|
Lavonas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|